Personalized warfarin therapy adjustment following mechanical heart valve replacement: The role of clinical and pharmacogenetic factors
Abstract. Warfarin remains to be the primary anticoagulant for patients with mechanical heart valve prostheses. Its narrow therapeutic index and high interindividual variability in required dosage necessitate a personalized approach to medicine dosing. The aim of the current article is to demonstrate the influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms, in combination with clinical factors, on warfarin dose selection, the dynamics of the International normalized ratio, and the time spent within the therapeutic range. A series of three clinical cases involving patients who underwent mechanical heart valve replacement and subsequently received pharmacogenetic testing for CYP2C9 (*2, *3), VKORC1 (-1639G>A), and CYP4F2 (rs2108622) is introduced. It is shown that the results of such testing are proving the individualized selection of an initial warfarin dose; however, final dosage adjustments must account for concurrent clinical factors – most notably the long-term use of amiodarone, which inhibits CYP2C9 as well as longitudinal monitoring of the international normalized ratio indexes.L.V. Selivanova, O.V. Dymova, D.A. Petrenko, I.S. Balkanzhaeva, I.V. Sychev, K.B. Mirzaev, D.A. Sychev
Keywords
warfarin
pharmacogenetics
CYP2C9
VKORC1
CYP4F2
heart valves replacement
amiodarone
personalized therapy
international normalized ratio
References
- World Health Organization. Cardiovascular diseases (CVDs). URL: https://www.who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (date of access – 15.05.2026).
- Клинические рекомендации. Аортальный стеноз. Ассоциация сердечно-сосудистых хирургов России, Общероссийская общественная организация «Российское кардиологическое общество», Общероссийская общественная организация содействия развитию лучевой диагностики и терапии «Российское общество рентгенологов и радиологов», Российское научное общество специалистов по рентгенэндоваскулярной диагностике и лечению, Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР), Национальная курортная ассоциация. Рубрикатор клинических рекомендаций Минздрава России. 2025. ID: 37_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/37_2 (дата обращений – 24.08.2026). [Clinical guidelines. Aortic stenosis. Association of Cardiovascular Surgeons of Russia, Russian Society of Cardiology, Russian Society of Radiologists and Radiologists, Russian Scientific Society of Specialists in Endovascular Diagnosis and Treatment, Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, National Health Resort Association. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2025. ID: 37_2. URL: https://cr.minzdrav.gov.ru/view-cr/37_2 (date of access – 24.08.2026) (In Russ.)].
- Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, et al.; ESC/EACTS Scientific Document Group. 2025 ESC/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635–736.
PMID: 40878295. https://doi.org/10.1093/eurheartj/ehaf194. Erratum in: Eur Heart J. 2026:ehag625. https://doi.org/10.1093/eurheartj/ehag625
- Johnson JA, Caudle KE, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther. 2017;102(3):397–404.
PMID: 28198005. PMCID: PMC5546947. https://doi.org/10.1002/cpt.668
- Зотова И.В., Никитин А.Г., Фаттахова Э.Н., Бровкин А.Н., Ходырев Д.С., Лаврикова Е.Ю. с соавт. Влияние полиморфизма генов CYP2C9 и VKORC1 на безопасность терапии варфарином. Клиническая практика. 2013;(4):3–10. [Zotova IV, Nikitin AG, Fattakhova EN, Brovkin AN, Khodyrev DS, Lavrikova EYu, et al. The affect of influence of genes' polymorphisms CYP2C9 and VKORC1 on the safety of the therapy by warfarin. Klinicheskaya praktika = Clinical Practice. 2013;(4):3–10 (In Russ.)]. EDN: RWEOOX.
- Сычев Д.А., Иващенко Д.В., Русин И.В. Влияние использования фармакогенетического тестирования на риск развития кровотечений и эпизодов чрезмерной гипокоагуляции при применении варфарина: первый метаанализ отечественных проспективных исследований. Терапевтический архив. 2014;86(4):64–71. [Sychev DA, Ivashchenko DV, Rusin IV. Impact of pharmacogenetic testing on the risk of bleedings and excessive hypocoagulation episodes in the use of warfarin: The first meta-analysis of Russian prospective studies Terapevticheskiy arkhiv = Therapeutic Archive. 2014;86(4):64–71 (In Russ.)]. EDN: SVPGNB.
- Демидов Р.О., Лапшина С.А., Якупова С.П., Мухина Р.Г. Дисплазия соединительной ткани: современные подходы к клинике, диагностике и лечению. Практическая медицина. 2015;(4–2):37–40. [Demidov RO, Lapshina SA, Yakupova SP, Mukhina RG. Connective tissue dysplasia: Current approaches to clinical picture, diagnosis and treatment. Practicheskaya meditsina = Practical Medicine. 2015;(4–2):37–40 (In Russ.)]. EDN: UABIMX.
- Селиванова Л.В., Лукина М.В., Юдин В.С., Петренко Д.А., Вилижинская К.А., Гилевская Ю.С. с соавт. Фармакогенетический подход к назначению лекарственных препаратов у кардиохирургических пациентов с высоким риском осложнений. Фармакогенетика и фармакогеномика. 2026;(2):70–81. [Selivanova LV, Lukina MV, Yudin VS, Petrenko DA, Vilizhinskaya KA, Gilevskaya YuS, et al. Pharmacogenetic approach to prescribing medications in cardiac surgery patients at high risk of complications. Farmakogenetika i farmakogenomika = Pharmacogenetics and Pharmacogenomics. 2026;(2):70–81 (In Russ.)].
EDN: FSWEGZ. https://doi.org/10.37489/2588-0527-0012
- Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106–12.
PMID: 18250228 PMCID: PMC2288721. https://doi.org/10.1182/blood-2007-11-122010
- Maleki O, Gharechahi J. Association of VKORC1 and CYP2C9 gene polymorphisms with warfarin dose requirements in a representative Iranian population with cardiac valve replacement surgery. Pharmacogenet Genomics. 2025;35(7):214–20.
PMID: 40511772. https://doi.org/10.1097/FPC.0000000000000571
- Li JX, Kim MH, Song K, Guo LZ, Jin EZ, Kim SJ, et al. Impact of VKORC1, CYP2C9, and CYP4F2 polymorphisms on optimal warfarin dose: Does ethnicity matters? Am J Ther. 2021;28(4):e461–68.
PMID: 34228652. https://doi.org/10.1097/MJT.0000000000000845
- Badak TO, Cereb F, Ucak HA, Uncu H, Ozalp O, Anlas O. The influence of genetic polymorphisms on warfarin dosage requirements in cardiac valve surgery patients. Cukurova Anestezi ve Cerrahi Bilimler Dergisi. 2024;7(2):104–7.
https://doi.org/10.36516/jocass.1472877
- Wang X, Zhao D, Ma J, Wang X, Liu J. Correlation between metabolic parameters and warfarin dose in patients with heart valve replacement of different genotypes. Rev Cardiovasc Med. 2024;25(4):128.
PMID: 39076565. PMCID: PMC11264039. https://doi.org/10.31083/j.rcm2504128
About the Authors
Lyubov V. Selivanova, MD, head of the Centralized Department of clinical pharmacology, clinical pharmacologist at Scientific and Clinical Center No. 1, Academician B.V. Petrovsky Russian Research Center of Surgery, Moscow, Russian Federation.E-mail: lubovlechit711@gmail.com
ORCID: https://orcid.org/0000-0003-2121-588X. eLibrary SPIN: 3941-0867
Olga V. Dymova, MD, PhD (Medicine), head of the Scientific and Clinical Laboratory, Academician B.V. Petrovsky Russian Research Center of Surgery, Moscow, Russian Federation.
E-mail: dimovaolga@gmail.com
ORCID: https://orcid.org/0000-0003-2008-6350
Daria A. Petrenko, MD, clinical pharmacologist, junior researcher at Scientific and Clinical Center No. 1, Academician B.V. Petrovsky Russian Research Center of Surgery, Moscow, Russian Federation.
E-mail: petrenkodasha17@yandex.ru
ORCID: https://orcid.org/0000-0001-5849-5585. eLibrary SPIN: 4382-1502
Irina S. Balkanzhayeva, MD, clinical resident of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation.
E-mail: irina.balkanzhaeva@mail.ru
Ivan V. Sychev, MD, researcher at the World-Class Genomic Research Center “Center for Predictive Genetics, Pharmacogenetics, and Personalized Therapy”, Academician B.V. Petrovsky Russian Research Center of Surgery, Moscow, Russian Federation.
E-mail: sychev_iv@bk.ru
ORCID: https://orcid.org/0000-0003-0227-2651
Karin B. Mirzaev, MD, Dr. Sci. (Medicine), associate professor, deputy head of the World-Class Genomic Research Center “Center for Predictive Genetics, Pharmacogenetics, and Personalized Therapy”, Academician B.V. Petrovsky Russian Research Center of Surgery; professor of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education, Moscow, Russian Federation.
E-mail: karin05doc@yandex.ru
ORCID: https://orcid.org/0000-0002-9307-4994. eLibrary SPIN: 8308-7599
Dmitry A. Sychev, MD, Dr. Sci. (Medicine), professor, academician of RAS, Honored Scientist of the Russian Federation, scientific director of the World-Class Genomic Research Center “Center for Predictive Genetics, Pharmacogenetics, and Personalized Therapy”, Academician B.V. Petrovsky Russian Research Center of Surgery; head of the Department of clinical pharmacology and therapy named after academician B.E. Votchal, Russian Medical Academy of Continuous Professional Education; president of the Eurasian Association of Clinical Pharmacology and Pharmacovigilance, Moscow, Russian Federation.
E-mail: dimasychev@mail.ru
ORCID: https://orcid.org/0000-0002-4496-3680. eLibrary SPIN: 4525-7556



